Intellipharmaceutics International Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Isa Odidi
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 26.5yrs |
| CEO ownership | n/a |
| Management average tenure | 26.5yrs |
| Board average tenure | 18.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2023 | n/a | n/a | -US$3m |
| May 31 2023 | n/a | n/a | -US$2m |
| Feb 28 2023 | n/a | n/a | -US$2m |
| Nov 30 2022 | US$348k | US$335k | -US$3m |
| Aug 31 2022 | n/a | n/a | -US$4m |
| May 31 2022 | n/a | n/a | -US$5m |
| Feb 28 2022 | n/a | n/a | -US$5m |
| Nov 30 2021 | US$375k | US$361k | -US$5m |
| Aug 31 2021 | n/a | n/a | -US$5m |
| May 31 2021 | n/a | n/a | -US$3m |
| Feb 28 2021 | n/a | n/a | -US$3m |
| Nov 30 2020 | US$363k | US$349k | -US$3m |
| Aug 31 2020 | n/a | n/a | -US$3m |
| May 31 2020 | n/a | n/a | -US$6m |
| Feb 29 2020 | n/a | n/a | -US$7m |
| Nov 30 2019 | US$560k | US$340k | -US$8m |
| Aug 31 2019 | n/a | n/a | -US$11m |
| May 31 2019 | n/a | n/a | -US$13m |
| Feb 28 2019 | n/a | n/a | -US$14m |
| Nov 30 2018 | US$1m | US$350k | -US$14m |
| Aug 31 2018 | n/a | n/a | -US$12m |
| May 31 2018 | n/a | n/a | -US$11m |
| Feb 28 2018 | n/a | n/a | -US$10m |
| Nov 30 2017 | US$2m | US$343k | -US$9m |
Compensation vs Market: Insufficient data to establish whether Isa's total compensation is reasonable compared to companies of similar size in the Canadian market.
Compensation vs Earnings: Isa's compensation has been consistent with company performance over the past year.
CEO
Isa Odidi (66 yo)
26.5yrs
Tenure
US$347,941
Compensation
Dr. Isa Odidi, Ph D., MBA has been the Chief Executive Officer and Co-Chief Scientific Officer at IntelliPharmaCeutics International Inc. since September 1, 2004. In 1998, Dr. Odidi co-founded Intellipharm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 26.5yrs | US$347.94k | no data | |
| President | 26.5yrs | US$347.94k | no data | |
| Vice-President of Chemistry & Analytical Services | 19.5yrs | US$119.93k | 0.0082% CA$ 217.4 | |
| Controller | no data | no data | no data |
26.5yrs
Average Tenure
66yo
Average Age
Experienced Management: IPCI.H's management team is seasoned and experienced (26.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$347.94k | no data | |
| President | 19.8yrs | US$347.94k | no data | |
| Independent Director | 18.3yrs | US$34.94k | 0.0023% CA$ 60.1 | |
| Independent Non-Executive Director | 6.2yrs | US$31.22k | no data | |
| Independent Non-Executive Director | 5.5yrs | US$31.22k | no data |
18.3yrs
Average Tenure
65yo
Average Age
Experienced Board: IPCI.H's board of directors are seasoned and experienced ( 18.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/30 04:43 |
| End of Day Share Price | 2024/07/26 00:00 |
| Earnings | 2023/08/31 |
| Annual Earnings | 2022/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Intellipharmaceutics International Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Raymond Deacon | Brean Capital |
| Jonathan Aschoff | Brean Capital |